Titre : Galectine -3

Galectine -3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Pilot Projects
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Galectine -3 : Questions médicales les plus fréquentes", "headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-02-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Galectine -3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Galectines", "url": "https://questionsmedicales.fr/mesh/D037161", "about": { "@type": "MedicalCondition", "name": "Galectines", "code": { "@type": "MedicalCode", "code": "D037161", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.503.307" } } }, "about": { "@type": "MedicalCondition", "name": "Galectine -3", "alternateName": "Galectin 3", "code": { "@type": "MedicalCode", "code": "D037502", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Çiğdem Yücel", "url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey." } }, { "@type": "Person", "name": "Aybeniz Civan Kahve", "url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve", "affiliation": { "@type": "Organization", "name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Işık Batuhan Çakmak", "url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak", "affiliation": { "@type": "Organization", "name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey." } }, { "@type": "Person", "name": "Erol Göka", "url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka", "affiliation": { "@type": "Organization", "name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Massiullah Shafaq-Zadah", "url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah", "affiliation": { "@type": "Organization", "name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "AI + Ethics Curricula for Middle School Youth: Lessons Learned from Three Project-Based Curricula.", "datePublished": "2022-08-01", "url": "https://questionsmedicales.fr/article/35935456", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s40593-022-00298-y" } }, { "@type": "ScholarlyArticle", "name": "Aetiology and outcomes of prolonged neonatal jaundice in tertiary centres: data from the China Neonatal Genome Project.", "datePublished": "2022-07-18", "url": "https://questionsmedicales.fr/article/35851034", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/archdischild-2021-323413" } }, { "@type": "ScholarlyArticle", "name": "Lessons learnt from delivering the public and patient involvement forums within a younger onset dementia project.", "datePublished": "2022-07-14", "url": "https://questionsmedicales.fr/article/35833723", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1177/14713012221110006" } }, { "@type": "ScholarlyArticle", "name": "How well have CMIP3, CMIP5 and CMIP6 future climate projections portrayed the recently observed warming.", "datePublished": "2022-07-14", "url": "https://questionsmedicales.fr/article/35835803", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-16264-6" } }, { "@type": "ScholarlyArticle", "name": "Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China.", "datePublished": "2022-07-08", "url": "https://questionsmedicales.fr/article/35875035", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fpubh.2022.938770" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Lectines", "item": "https://questionsmedicales.fr/mesh/D037102" }, { "@type": "ListItem", "position": 5, "name": "Galectines", "item": "https://questionsmedicales.fr/mesh/D037161" }, { "@type": "ListItem", "position": 6, "name": "Galectine -3", "item": "https://questionsmedicales.fr/mesh/D037502" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Galectine -3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Galectine -3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Galectine -3", "description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Galectine -3", "description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Galectine -3", "description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Galectine -3", "description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Galectine -3", "description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Galectine -3", "description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Pilot+Projects&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer le taux de galectine-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le taux de galectine-3 se mesure par un test sanguin spécifique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés." } }, { "@type": "Question", "name": "La galectine-3 est-elle un biomarqueur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies." } }, { "@type": "Question", "name": "Quels médecins évaluent la galectine-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cardiologues et oncologues évaluent souvent la galectine-3." } }, { "@type": "Question", "name": "Peut-on détecter la galectine-3 dans l'urine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la galectine-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle est associée à des symptômes d'inflammation et de fibrose." } }, { "@type": "Question", "name": "La galectine-3 cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cardiaques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme l'essoufflement peuvent être présents." } }, { "@type": "Question", "name": "La galectine-3 est-elle liée à la fatigue ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être associée à la fatigue dans des conditions inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la dyspnée peuvent être observés." } }, { "@type": "Question", "name": "Comment prévenir l'augmentation de la galectine-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la galectine-3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il des aliments à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments transformés et riches en sucres peut être bénéfique." } }, { "@type": "Question", "name": "Le stress affecte-t-il la galectine-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3." } }, { "@type": "Question", "name": "Des suppléments peuvent-ils aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques." } }, { "@type": "Question", "name": "Quels traitements ciblent la galectine-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies." } }, { "@type": "Question", "name": "La galectine-3 peut-elle être traitée par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments visent à réduire son activité dans le corps." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la galectine-3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches diététiques et des suppléments peuvent aider à la réguler." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la maladie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements dépendent de la maladie associée à la galectine-3." } }, { "@type": "Question", "name": "La thérapie génique peut-elle cibler la galectine-3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches explorent la thérapie génique pour moduler son expression." } }, { "@type": "Question", "name": "Quelles complications sont liées à la galectine-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Elle est liée à des complications cardiovasculaires et pulmonaires." } }, { "@type": "Question", "name": "La galectine-3 aggrave-t-elle les maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer." } }, { "@type": "Question", "name": "La galectine-3 influence-t-elle la fibrose ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives." } }, { "@type": "Question", "name": "Quels facteurs augmentent la galectine-3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la galectine-3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec les maladies auto-immunes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3." } } ] } ] }

Sources (10000 au total)

Aetiology and outcomes of prolonged neonatal jaundice in tertiary centres: data from the China Neonatal Genome Project.

To investigate the distribution of aetiologies and outcomes in neonates with prolonged neonatal jaundice.... An observational study.... Multiple tertiary centres from the China Neonatal Genome Project.... Term infants with jaundice lasting more than 14 days or preterm infants with jaundice lasting more than 21 days were recruited between 1 June 2016 and 30 June 2020.... Aetiology and outcomes were recorded from neonates with prolonged unconjugated hyperbilirubinaemia (PUCHB) and prolonged conjugated hyperbilirubinaemia (PCHB).... A total of 939 neonates were enrolled, and known aetiologies were identified in 84.1% of neonates (790 of 939). Among 411 neonates with PCHB, genetic disorders (27.2%, 112 of 411) were the leading aet... Known aetiologies were identified in approximately 80% of neonates in our cohort, and their overall outcomes were favourable. Genetic aetiology should be considered a priority in neonates with PCHB or...

Secular Trends in the Burden of Multiple Myeloma From 1990 to 2019 and Its Projection Until 2044 in China.

Multiple myeloma (MM) imposes a heavy burden in China. Understanding the secular trend of MM burden and projecting its future trend could facilitate appropriate public health planning and improve the ... Sex-specific incidence and mortality rates of MM in China from 1990 to 2019 were collected from the Global Burden of Disease 2019 study. The secular trend of MM burden was analyzed by joinpoint regres... From 1990 to 2019, the age-standardized incidence and mortality rates of MM continued to increase in males. For females, the age-standardized rates were stable in MM incidence and decreased in MM mort... The burden of MM in China is expected to continue to increase in the future, with significant sex difference. A comprehensive understanding of the risk characteristics and disease pattern of MM could ...

Characteristics of People Seeking Prescribed Cannabinoids for the Treatment of Chronic Pain: Evidence From Project Twenty 21.

Prescribed cannabinoids are now legal in the UK and increasingly being used for a variety of conditions, with one of the most frequent conditions being chronic pain. This paper describes the character... By 1st November 2021 data were available for 1,782 people who had sought treatment with medical cannabis as part of Project Twenty 21. The most common diagnosis among this cohort was chronic pain with... Of the 949 people reporting chronic pain as a primary condition 54.7% were male and their average age was 42.0 years (range = 18-84). Patients reported a low quality of life and high levels of comorbi... Consistent with findings in other national and international databases, chronic pain was the most common primary condition in this real world study of prescribed cannabinoids. There was considerable v...

Prevention of needle-stick injury among nurses in an acute ward of a hospital: a best practice implementation project.

This evidence implementation project aimed to identify barriers leading to needle-stick injuries (NSIs) and to develop implementation strategies to prevent NSIs in the acute ward of a hospital in cent... The incidence rate of NSIs was 5.6% in the acute ward of a hospital in Taiwan. NSIs commonly occur during the drawing of blood, intravenous insertion, needle recapping, or performing any procedure inv... A clinical audit was undertaken using the JBI Practical Application of Clinical Evidence System (PACES) and the Getting Research into Practice (GRiP) approach. Five audit criteria that represented bes... According to the pre-audit concerning the use of safety-engineered injection devices and safe use and disposal of needles, there was 14-15% compliance, which indicated poor compliance with current bes... This article suggests that standardized puncture prevention education and training enhanced nurses' awareness in the acute ward....